Navigation Links
Actavis Receives Approval of Generic Wellbutrin XL(R) 150mg in the U.S.
Date:12/1/2008

MORRISTOWN, N.J., Dec. 1 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 150mg. Distribution of the product has commenced.

Bupropion Hydrochloride extended-release tablets (XL), available in 150 & 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual U.S. sales of brand and generic Wellbutrin XL(R) were US$1,481 million for the 12 months ending September 2008 according to IMS Health data.

Commenting on the new approval, Doug Boothe, CEO of Actavis in the United States said:

"Bupropion XL 150mg, together with 300mg which was launched in August this year, offers significant value to our customers and patients. This approval also underscores Actavis' emphasis and capability in bringing complex controlled-release products to the marketplace."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
2. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
3. Actavis Extends Portfolio With Four New Products in the U.S.
4. Actavis Confirms its Patent Challenge of Kings Avinza(R)
5. Actavis Launches Amlodipine Tablets in the U.S.
6. Actavis Launches Carvedilol Tablets in the U.S.
7. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
8. EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
9. Melissa Murer Corrigan Receives Prestigious NOCA Leadership Award
10. ECO2 Plastics, Inc. Receives Favorable FDA Opinion Letter Approving the Use of Its Recycled Plastic Flake in Food Packaging Applications
11. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... from high school and while 84 percent of parents report speaking with their child ... control, pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... Sourced from ... has some unique properties including its unmatched natural purity of just 6 ppm TDS ... and crisp. , Nothing Water has been available in several ShopRite and FoodTown stores ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... to needy individuals and families from eight different sites throughout Miami-Dade and Broward ... Over 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... comprehensive in-house dental plan for all patients. Understanding that budget can play a ... patients a number of perks, including discounts on many valuable dental treatments. Options ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent ... a focus of public policymakers and system stakeholders in many states. To help ... Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , December 2, 2016 On Thursday, ... session in red, while the Dow Jones Industrial Average managed ... close of US markets, which prompted Stock-callers this morning to ... Inc. (NASDAQ: NUVA ), Smith & Nephew PLC ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
(Date:12/2/2016)... 2016 Research and Markets has announced ... Cancer - Technologies, Markets and Companies" to their offering. ... , , ... cancer The market value of drug delivery technologies and ... 2015-2025 are given according to organs involved and the types of ...
(Date:12/2/2016)... OLD LYME, Conn. , Dec. 1, 2016 /PRNewswire/ ... consulting, has announced the honor of being selected as ... that include: Simpson Healthcare Executives Website at the PLATINUM ... Directed Conversations Training Module at the GOLD Level, and ... At Simpson Healthcare Executives, we are ...
Breaking Medicine Technology: